rewirebio.iobenchmarks
Source

BioML-bench: Evaluation of AI Agents for End-to-End Biomedical ML

bioRxiv 2025.09.01.673319 version 3, posted 2025-09-28 (versions 1 and 2 posted 2025-09-04 and 2025-09-07) · Preprint

DOI: 10.1101/2025.09.01.673319Original source

What this source contributed

Records in this release that cite this source. A record can cite several sources.

Results

Values as the source printed them. Compare results only under compatible protocols, datasets and metrics.

Model or configurationMetricValueDatasetEvaluation
AIDE v6.3.3, GPT-4.1 backend (BioML-bench)Leaderboard percentile (mean over tasks in the domain; non-penalized: runs without a valid submission omitted)31.06 ± 8.88 percentBioML-bench v0.1-alpha drug discovery tasks (9 tasks)AIDE on BioML-bench drug discovery (non-penalized)
AIDE v6.3.3, GPT-4.1 backend (BioML-bench)Proportion (share of tasks where the agent reaches a public leaderboard medal threshold, MLE-bench definition (Section 3.4); non-penalized: runs without a valid submission omitted)7.4 ± 7.4 percentBioML-bench v0.1-alpha drug discovery tasks (9 tasks)AIDE on BioML-bench drug discovery (non-penalized)
AIDE v6.3.3, GPT-4.1 backend (BioML-bench)Proportion (share of tasks where the agent's mean score exceeds the median human leaderboard submission (Section 3.4 definition); non-penalized: runs without a valid submission omitted)30.6 ± 13.3 percentBioML-bench v0.1-alpha drug discovery tasks (9 tasks)AIDE on BioML-bench drug discovery (non-penalized)
AIDE v6.3.3, GPT-4.1 backend (BioML-bench)Leaderboard percentile (mean over tasks in the domain; penalized: runs without a valid submission scored as percentile 0)24.75 ± 7.23 percentBioML-bench v0.1-alpha drug discovery tasks (9 tasks)AIDE on BioML-bench drug discovery (penalized)
AIDE v6.3.3, GPT-4.1 backend (BioML-bench)Proportion (share of tasks that yield a valid, gradable submission (Section 3.4 definition); penalized: runs without a valid submission scored as percentile 0)80.6 percentBioML-bench v0.1-alpha drug discovery tasks (9 tasks)AIDE on BioML-bench drug discovery (penalized)
AIDE v6.3.3, GPT-4.1 backend (BioML-bench)Proportion (share of tasks where the agent reaches a public leaderboard medal threshold, MLE-bench definition (Section 3.4); penalized: runs without a valid submission scored as percentile 0)5.6 ± 5.6 percentBioML-bench v0.1-alpha drug discovery tasks (9 tasks)AIDE on BioML-bench drug discovery (penalized)
AIDE v6.3.3, GPT-4.1 backend (BioML-bench)Proportion (share of tasks where the agent's mean score exceeds the median human leaderboard submission (Section 3.4 definition); penalized: runs without a valid submission scored as percentile 0)25.0 ± 11.0 percentBioML-bench v0.1-alpha drug discovery tasks (9 tasks)AIDE on BioML-bench drug discovery (penalized)
AIDE v6.3.3, GPT-4.1 backend (BioML-bench)Leaderboard percentile (mean over tasks in the domain; non-penalized: runs without a valid submission omitted)35.99 ± 10.96 percentBioML-bench v0.1-alpha protein engineering tasks (6 tasks)AIDE on BioML-bench protein engineering (non-penalized)
AIDE v6.3.3, GPT-4.1 backend (BioML-bench)Proportion (share of tasks where the agent reaches a public leaderboard medal threshold, MLE-bench definition (Section 3.4); non-penalized: runs without a valid submission omitted)16.7 ± 11.4 percentBioML-bench v0.1-alpha protein engineering tasks (6 tasks)AIDE on BioML-bench protein engineering (non-penalized)
AIDE v6.3.3, GPT-4.1 backend (BioML-bench)Proportion (share of tasks where the agent's mean score exceeds the median human leaderboard submission (Section 3.4 definition); non-penalized: runs without a valid submission omitted)38.9 ± 15.9 percentBioML-bench v0.1-alpha protein engineering tasks (6 tasks)AIDE on BioML-bench protein engineering (non-penalized)
AIDE v6.3.3, GPT-4.1 backend (BioML-bench)Leaderboard percentile (mean over tasks in the domain; penalized: runs without a valid submission scored as percentile 0)24.50 ± 6.90 percentBioML-bench v0.1-alpha protein engineering tasks (6 tasks)AIDE on BioML-bench protein engineering (penalized)
AIDE v6.3.3, GPT-4.1 backend (BioML-bench)Proportion (share of tasks that yield a valid, gradable submission (Section 3.4 definition); penalized: runs without a valid submission scored as percentile 0)75.0 percentBioML-bench v0.1-alpha protein engineering tasks (6 tasks)AIDE on BioML-bench protein engineering (penalized)
AIDE v6.3.3, GPT-4.1 backend (BioML-bench)Proportion (share of tasks where the agent reaches a public leaderboard medal threshold, MLE-bench definition (Section 3.4); penalized: runs without a valid submission scored as percentile 0)12.5 ± 8.5 percentBioML-bench v0.1-alpha protein engineering tasks (6 tasks)AIDE on BioML-bench protein engineering (penalized)
AIDE v6.3.3, GPT-4.1 backend (BioML-bench)Proportion (share of tasks where the agent's mean score exceeds the median human leaderboard submission (Section 3.4 definition); penalized: runs without a valid submission scored as percentile 0)25.0 ± 9.1 percentBioML-bench v0.1-alpha protein engineering tasks (6 tasks)AIDE on BioML-bench protein engineering (penalized)
AIDE v6.3.3, GPT-4.1 backend (BioML-bench)Leaderboard percentile (mean over tasks in the domain; non-penalized: runs without a valid submission omitted)60.67 ± 11.16 percentBioML-bench v0.1-alpha single cell omics tasks (5 tasks)AIDE on BioML-bench single cell omics (non-penalized)
AIDE v6.3.3, GPT-4.1 backend (BioML-bench)Proportion (share of tasks where the agent reaches a public leaderboard medal threshold, MLE-bench definition (Section 3.4); non-penalized: runs without a valid submission omitted)33.3 ± 19.0 percentBioML-bench v0.1-alpha single cell omics tasks (5 tasks)AIDE on BioML-bench single cell omics (non-penalized)
AIDE v6.3.3, GPT-4.1 backend (BioML-bench)Proportion (share of tasks where the agent's mean score exceeds the median human leaderboard submission (Section 3.4 definition); non-penalized: runs without a valid submission omitted)58.3 ± 16.7 percentBioML-bench v0.1-alpha single cell omics tasks (5 tasks)AIDE on BioML-bench single cell omics (non-penalized)
AIDE v6.3.3, GPT-4.1 backend (BioML-bench)Rank (mean relative rank among the five Table 4 agents (Dummy, MLAgentBench, AIDE, STELLA, Biomni) by leaderboard percentile, over tasks in the domain; non-penalized: runs without a valid submission omitted)2.30 ± 0.54 unitlessBioML-bench v0.1-alpha single cell omics tasks (5 tasks)AIDE on BioML-bench single cell omics (non-penalized)
AIDE v6.3.3, GPT-4.1 backend (BioML-bench)Leaderboard percentile (mean over tasks in the domain; penalized: runs without a valid submission scored as percentile 0)53.17 ± 14.86 percentBioML-bench v0.1-alpha single cell omics tasks (5 tasks)AIDE on BioML-bench single cell omics (penalized)
AIDE v6.3.3, GPT-4.1 backend (BioML-bench)Proportion (share of tasks that yield a valid, gradable submission (Section 3.4 definition); penalized: runs without a valid submission scored as percentile 0)85.0 percentBioML-bench v0.1-alpha single cell omics tasks (5 tasks)AIDE on BioML-bench single cell omics (penalized)
AIDE v6.3.3, GPT-4.1 backend (BioML-bench)Proportion (share of tasks where the agent reaches a public leaderboard medal threshold, MLE-bench definition (Section 3.4); penalized: runs without a valid submission scored as percentile 0)35.0 ± 18.7 percentBioML-bench v0.1-alpha single cell omics tasks (5 tasks)AIDE on BioML-bench single cell omics (penalized)
AIDE v6.3.3, GPT-4.1 backend (BioML-bench)Proportion (share of tasks where the agent's mean score exceeds the median human leaderboard submission (Section 3.4 definition); penalized: runs without a valid submission scored as percentile 0)55.0 ± 16.6 percentBioML-bench v0.1-alpha single cell omics tasks (5 tasks)AIDE on BioML-bench single cell omics (penalized)
AIDE v6.3.3, GPT-4.1 backend (BioML-bench)Rank (mean relative rank among the five Table 4 agents (Dummy, MLAgentBench, AIDE, STELLA, Biomni) by leaderboard percentile, over tasks in the domain; penalized: runs without a valid submission scored as percentile 0)2.70 ± 0.44 unitlessBioML-bench v0.1-alpha single cell omics tasks (5 tasks)AIDE on BioML-bench single cell omics (penalized)
Biomni v0.0.5, Claude Sonnet 4 backend (BioML-bench)Leaderboard percentile (mean over tasks in the domain; non-penalized: runs without a valid submission omitted)32.55 ± 8.61 percentBioML-bench v0.1-alpha drug discovery tasks (9 tasks)Biomni on BioML-bench drug discovery (non-penalized)
Biomni v0.0.5, Claude Sonnet 4 backend (BioML-bench)Proportion (share of tasks where the agent reaches a public leaderboard medal threshold, MLE-bench definition (Section 3.4); non-penalized: runs without a valid submission omitted)13.9 ± 11.1 percentBioML-bench v0.1-alpha drug discovery tasks (9 tasks)Biomni on BioML-bench drug discovery (non-penalized)
Biomni v0.0.5, Claude Sonnet 4 backend (BioML-bench)Proportion (share of tasks where the agent's mean score exceeds the median human leaderboard submission (Section 3.4 definition); non-penalized: runs without a valid submission omitted)30.6 ± 12.3 percentBioML-bench v0.1-alpha drug discovery tasks (9 tasks)Biomni on BioML-bench drug discovery (non-penalized)
Biomni v0.0.5, Claude Sonnet 4 backend (BioML-bench)Leaderboard percentile (mean over tasks in the domain; penalized: runs without a valid submission scored as percentile 0)32.55 ± 8.61 percentBioML-bench v0.1-alpha drug discovery tasks (9 tasks)Biomni on BioML-bench drug discovery (penalized)
Biomni v0.0.5, Claude Sonnet 4 backend (BioML-bench)Proportion (share of tasks that yield a valid, gradable submission (Section 3.4 definition); penalized: runs without a valid submission scored as percentile 0)100.0 percentBioML-bench v0.1-alpha drug discovery tasks (9 tasks)Biomni on BioML-bench drug discovery (penalized)
Biomni v0.0.5, Claude Sonnet 4 backend (BioML-bench)Proportion (share of tasks where the agent reaches a public leaderboard medal threshold, MLE-bench definition (Section 3.4); penalized: runs without a valid submission scored as percentile 0)13.9 ± 11.1 percentBioML-bench v0.1-alpha drug discovery tasks (9 tasks)Biomni on BioML-bench drug discovery (penalized)
Biomni v0.0.5, Claude Sonnet 4 backend (BioML-bench)Proportion (share of tasks where the agent's mean score exceeds the median human leaderboard submission (Section 3.4 definition); penalized: runs without a valid submission scored as percentile 0)30.6 ± 12.3 percentBioML-bench v0.1-alpha drug discovery tasks (9 tasks)Biomni on BioML-bench drug discovery (penalized)
Biomni v0.0.5, Claude Sonnet 4 backend (BioML-bench)Leaderboard percentile (mean over tasks in the domain; non-penalized: runs without a valid submission omitted)29.93 ± 11.04 percentBioML-bench v0.1-alpha protein engineering tasks (6 tasks)Biomni on BioML-bench protein engineering (non-penalized)
Biomni v0.0.5, Claude Sonnet 4 backend (BioML-bench)Proportion (share of tasks where the agent reaches a public leaderboard medal threshold, MLE-bench definition (Section 3.4); non-penalized: runs without a valid submission omitted)25.0 ± 17.1 percentBioML-bench v0.1-alpha protein engineering tasks (6 tasks)Biomni on BioML-bench protein engineering (non-penalized)
Biomni v0.0.5, Claude Sonnet 4 backend (BioML-bench)Proportion (share of tasks where the agent's mean score exceeds the median human leaderboard submission (Section 3.4 definition); non-penalized: runs without a valid submission omitted)25.0 ± 17.1 percentBioML-bench v0.1-alpha protein engineering tasks (6 tasks)Biomni on BioML-bench protein engineering (non-penalized)
Biomni v0.0.5, Claude Sonnet 4 backend (BioML-bench)Leaderboard percentile (mean over tasks in the domain; penalized: runs without a valid submission scored as percentile 0)29.93 ± 11.04 percentBioML-bench v0.1-alpha protein engineering tasks (6 tasks)Biomni on BioML-bench protein engineering (penalized)
Biomni v0.0.5, Claude Sonnet 4 backend (BioML-bench)Proportion (share of tasks that yield a valid, gradable submission (Section 3.4 definition); penalized: runs without a valid submission scored as percentile 0)100.0 percentBioML-bench v0.1-alpha protein engineering tasks (6 tasks)Biomni on BioML-bench protein engineering (penalized)
Biomni v0.0.5, Claude Sonnet 4 backend (BioML-bench)Proportion (share of tasks where the agent reaches a public leaderboard medal threshold, MLE-bench definition (Section 3.4); penalized: runs without a valid submission scored as percentile 0)25.0 ± 17.1 percentBioML-bench v0.1-alpha protein engineering tasks (6 tasks)Biomni on BioML-bench protein engineering (penalized)
Biomni v0.0.5, Claude Sonnet 4 backend (BioML-bench)Proportion (share of tasks where the agent's mean score exceeds the median human leaderboard submission (Section 3.4 definition); penalized: runs without a valid submission scored as percentile 0)25.0 ± 17.1 percentBioML-bench v0.1-alpha protein engineering tasks (6 tasks)Biomni on BioML-bench protein engineering (penalized)
Biomni v0.0.5, Claude Sonnet 4 backend (BioML-bench)Leaderboard percentile (mean over tasks in the domain; non-penalized: runs without a valid submission omitted)55.62 ± 10.32 percentBioML-bench v0.1-alpha single cell omics tasks (5 tasks)Biomni on BioML-bench single cell omics (non-penalized)
Biomni v0.0.5, Claude Sonnet 4 backend (BioML-bench)Proportion (share of tasks where the agent reaches a public leaderboard medal threshold, MLE-bench definition (Section 3.4); non-penalized: runs without a valid submission omitted)30.0 ± 14.6 percentBioML-bench v0.1-alpha single cell omics tasks (5 tasks)Biomni on BioML-bench single cell omics (non-penalized)
Biomni v0.0.5, Claude Sonnet 4 backend (BioML-bench)Proportion (share of tasks where the agent's mean score exceeds the median human leaderboard submission (Section 3.4 definition); non-penalized: runs without a valid submission omitted)60.0 ± 20.3 percentBioML-bench v0.1-alpha single cell omics tasks (5 tasks)Biomni on BioML-bench single cell omics (non-penalized)
Biomni v0.0.5, Claude Sonnet 4 backend (BioML-bench)Rank (mean relative rank among the five Table 4 agents (Dummy, MLAgentBench, AIDE, STELLA, Biomni) by leaderboard percentile, over tasks in the domain; non-penalized: runs without a valid submission omitted)2.20 ± 0.58 unitlessBioML-bench v0.1-alpha single cell omics tasks (5 tasks)Biomni on BioML-bench single cell omics (non-penalized)
Biomni v0.0.5, Claude Sonnet 4 backend (BioML-bench)Leaderboard percentile (mean over tasks in the domain; penalized: runs without a valid submission scored as percentile 0)55.62 ± 10.32 percentBioML-bench v0.1-alpha single cell omics tasks (5 tasks)Biomni on BioML-bench single cell omics (penalized)
Biomni v0.0.5, Claude Sonnet 4 backend (BioML-bench)Proportion (share of tasks that yield a valid, gradable submission (Section 3.4 definition); penalized: runs without a valid submission scored as percentile 0)100.0 percentBioML-bench v0.1-alpha single cell omics tasks (5 tasks)Biomni on BioML-bench single cell omics (penalized)
Biomni v0.0.5, Claude Sonnet 4 backend (BioML-bench)Proportion (share of tasks where the agent reaches a public leaderboard medal threshold, MLE-bench definition (Section 3.4); penalized: runs without a valid submission scored as percentile 0)30.0 ± 14.6 percentBioML-bench v0.1-alpha single cell omics tasks (5 tasks)Biomni on BioML-bench single cell omics (penalized)
Biomni v0.0.5, Claude Sonnet 4 backend (BioML-bench)Proportion (share of tasks where the agent's mean score exceeds the median human leaderboard submission (Section 3.4 definition); penalized: runs without a valid submission scored as percentile 0)60.0 ± 20.3 percentBioML-bench v0.1-alpha single cell omics tasks (5 tasks)Biomni on BioML-bench single cell omics (penalized)
Biomni v0.0.5, Claude Sonnet 4 backend (BioML-bench)Rank (mean relative rank among the five Table 4 agents (Dummy, MLAgentBench, AIDE, STELLA, Biomni) by leaderboard percentile, over tasks in the domain; penalized: runs without a valid submission scored as percentile 0)1.60 ± 0.40 unitlessBioML-bench v0.1-alpha single cell omics tasks (5 tasks)Biomni on BioML-bench single cell omics (penalized)
Dummy agent (BioML-bench)Leaderboard percentile (mean over tasks in the domain; non-penalized: runs without a valid submission omitted)1.11 ± 1.11 percentBioML-bench v0.1-alpha drug discovery tasks (9 tasks)Dummy on BioML-bench drug discovery (non-penalized)
Dummy agent (BioML-bench)Proportion (share of tasks where the agent reaches a public leaderboard medal threshold, MLE-bench definition (Section 3.4); non-penalized: runs without a valid submission omitted)0.0 ± 0.0 percentBioML-bench v0.1-alpha drug discovery tasks (9 tasks)Dummy on BioML-bench drug discovery (non-penalized)
Dummy agent (BioML-bench)Proportion (share of tasks where the agent's mean score exceeds the median human leaderboard submission (Section 3.4 definition); non-penalized: runs without a valid submission omitted)0.0 ± 0.0 percentBioML-bench v0.1-alpha drug discovery tasks (9 tasks)Dummy on BioML-bench drug discovery (non-penalized)
Dummy agent (BioML-bench)Leaderboard percentile (mean over tasks in the domain; penalized: runs without a valid submission scored as percentile 0)1.11 ± 1.11 percentBioML-bench v0.1-alpha drug discovery tasks (9 tasks)Dummy on BioML-bench drug discovery (penalized)

Claims

Statements this source supports, each with where in the source it was checked.

  • benchmark-biomlbench: attributes.limitations: Limitations Agent scores are ranked against human leaderboards which are largely expert-populated; public leaderboards inevitably reflect a mix of participant expertise, effort, and compute budgets. (Figure 1 caption; Section 5.1, second paragraph)
  • benchmark-biomlbench: attributes.limitations: Limitations The framework is adapted from MLE-bench, but with key modifications to support biomedical contexts. (Section 3.1, first paragraph)
  • benchmark-biomlbench: attributes.limitations: Limitations Imaging tasks used a single NVIDIA L4 GPU (16 vCPUs, 64 GB RAM) with a 16-hour wall-clock limit. All other tasks used CPU-only machines with identical specifications and an 8-hour limit. (Section 3.4, last paragraph)
  • benchmark-biomlbench: attributes.limitations: Limitations At evaluation time, we used the latest compatible LLM backends: GPT-4.1 for MLAgentBench and AIDE, Claude Sonnet 4 for Biomni, and the OpenRouter default for STELLA. (Section 3.3)
  • benchmark-biomlbench: attributes.scope_note: Scope note BioML-bench spans four domains (protein engineering, single-cell omics, biomedical imaging, and drug discovery) with tasks that require agents to parse a task description, build a pipeline, implement models, and submit predictions graded by established metrics (e.g., AUROC, Spearman). (Abstract)
  • config-aide-gpt-4-1: attributes.version: Version AIDE (v6.3.3) (Section 3.3)
  • config-biomni-claude-sonnet-4: attributes.version: Version Biomni (specifically, v0.0.5) (Section 3.3)
  • data-protein-engineering-tasks: attributes.limitations[0]: Limitations[0] The paper's Table 3 and the repository task list disagree on two protein engineering assays (SPA_STAAU versus SBI_STAAM; PSAE_PICP2 indels versus substitutions); see the source limitations. (Table 3; repository experiments/biomlbench_v0.1a.txt at commit 673f3d8)
  • source-miller2025-v3: attributes.limitations[2]: Limitations[2] Table 3 names two protein engineering tasks differently from the repository's task list at commit 673f3d8 (experiments/biomlbench_v0.1a.txt): SPA_STAAU_Tsuboyama_2023 (protein A) versus SBI_STAAM_Tsuboyama_2023_2JVG (immunoglobulin-binding protein Sbi, single substitutions), and PSAE_PICP2_indels versus PSAE_PICP2_Tsuboyama_2023_1PSE (the substitution assay; the repository also holds a separate _indels task). Which of these assays were run is unresolved. The third label difference, CBX4_HUMAN_multi-sub versus CBX4_HUMAN_Tsuboyama_2023_2K28, is the same assay: the repository description of 2K28 says it contains multi-substitution variants of CBX4_HUMAN. (Table 3, protein engineering rows; repository experiments/biomlbench_v0.1a.txt and biomlbench/tasks/proteingym-dms/{SBI_STAAM_Tsuboyama_2023_2JVG,PSAE_PICP2_Tsuboyama_2023_1PSE,CBX4_HUMAN_Tsuboyama_2023_2K28}/description.md at commit 673f3d8)

Models, benchmarks and other records

Models (2)

Methods (4)

Configurations (5)

Benchmarks (1)

Tasks (20)

Protocols (3)

Dataset subsets (3)

Evaluations (30)

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

23 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-11-02-a7f03c9e55a5
Property and statementOriginal source and locationReview and provenance
Access and reuse
CC-BY-4.0 permits redistribution of the article bytes.
Source metadata
BioML-bench: Evaluation of AI Agents for End-to-End Biomedical ML

Original source ↗

No field-specific location recorded

Version: bioRxiv 2025.09.01.673319 version 3, posted 2025-09-28 (versions 1 and 2 posted 2025-09-04 and 2025-09-07)
Retrieved: 2026-10-13T12:38:42Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.access_and_reuse

Source artifact SHA-256: 875cb3519dac9b0ec51c35224e1fc90b107b0676a4cc7c22cecb56eb8ac38b35

Hash scope: SHA-256 of the PDF bytes as downloaded 2026-10-13T12:38:42Z. bioRxiv rewrites the XMP dates and document IDs, the Info ModDate and the trailer /ID on download, so a re-download does not reproduce the hash; the review found a fresh copy differing only in those 43 bytes, with an identical text layer.

Inspected artifact

Archive note
Not archived in the batch: the PDF is 2,282,513 bytes and the repository keeps releases small. The artifact_sha256 pins the bytes that were read.
Source metadata
BioML-bench: Evaluation of AI Agents for End-to-End Biomedical ML

Original source ↗

No field-specific location recorded

Version: bioRxiv 2025.09.01.673319 version 3, posted 2025-09-28 (versions 1 and 2 posted 2025-09-04 and 2025-09-07)
Retrieved: 2026-10-13T12:38:42Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.archive_note

Source artifact SHA-256: 875cb3519dac9b0ec51c35224e1fc90b107b0676a4cc7c22cecb56eb8ac38b35

Hash scope: SHA-256 of the PDF bytes as downloaded 2026-10-13T12:38:42Z. bioRxiv rewrites the XMP dates and document IDs, the Info ModDate and the trailer /ID on download, so a re-download does not reproduce the hash; the review found a fresh copy differing only in those 43 bytes, with an identical text layer.

Inspected artifact

Artifact SHA-256
875cb3519dac9b0ec51c35224e1fc90b107b0676a4cc7c22cecb56eb8ac38b35
Source metadata
BioML-bench: Evaluation of AI Agents for End-to-End Biomedical ML

Original source ↗

No field-specific location recorded

Version: bioRxiv 2025.09.01.673319 version 3, posted 2025-09-28 (versions 1 and 2 posted 2025-09-04 and 2025-09-07)
Retrieved: 2026-10-13T12:38:42Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.artifact_sha256

Source artifact SHA-256: 875cb3519dac9b0ec51c35224e1fc90b107b0676a4cc7c22cecb56eb8ac38b35

Hash scope: SHA-256 of the PDF bytes as downloaded 2026-10-13T12:38:42Z. bioRxiv rewrites the XMP dates and document IDs, the Info ModDate and the trailer /ID on download, so a re-download does not reproduce the hash; the review found a fresh copy differing only in those 43 bytes, with an identical text layer.

Inspected artifact

Artifact url
https://www.biorxiv.org/content/10.1101/2025.09.01.673319v3.full.pdf
Source metadata
BioML-bench: Evaluation of AI Agents for End-to-End Biomedical ML

Original source ↗

No field-specific location recorded

Version: bioRxiv 2025.09.01.673319 version 3, posted 2025-09-28 (versions 1 and 2 posted 2025-09-04 and 2025-09-07)
Retrieved: 2026-10-13T12:38:42Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.artifact_url

Source artifact SHA-256: 875cb3519dac9b0ec51c35224e1fc90b107b0676a4cc7c22cecb56eb8ac38b35

Hash scope: SHA-256 of the PDF bytes as downloaded 2026-10-13T12:38:42Z. bioRxiv rewrites the XMP dates and document IDs, the Info ModDate and the trailer /ID on download, so a re-download does not reproduce the hash; the review found a fresh copy differing only in those 43 bytes, with an identical text layer.

Inspected artifact

Doi
10.1101/2025.09.01.673319
Source metadata
BioML-bench: Evaluation of AI Agents for End-to-End Biomedical ML

Original source ↗

No field-specific location recorded

Version: bioRxiv 2025.09.01.673319 version 3, posted 2025-09-28 (versions 1 and 2 posted 2025-09-04 and 2025-09-07)
Retrieved: 2026-10-13T12:38:42Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.doi

Source artifact SHA-256: 875cb3519dac9b0ec51c35224e1fc90b107b0676a4cc7c22cecb56eb8ac38b35

Hash scope: SHA-256 of the PDF bytes as downloaded 2026-10-13T12:38:42Z. bioRxiv rewrites the XMP dates and document IDs, the Info ModDate and the trailer /ID on download, so a re-download does not reproduce the hash; the review found a fresh copy differing only in those 43 bytes, with an identical text layer.

Inspected artifact

Extraction method
pdftotext -layout text layer, parsed by extract/extract_biomlbench.py
Source metadata
BioML-bench: Evaluation of AI Agents for End-to-End Biomedical ML

Original source ↗

No field-specific location recorded

Version: bioRxiv 2025.09.01.673319 version 3, posted 2025-09-28 (versions 1 and 2 posted 2025-09-04 and 2025-09-07)
Retrieved: 2026-10-13T12:38:42Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.extraction_method

Source artifact SHA-256: 875cb3519dac9b0ec51c35224e1fc90b107b0676a4cc7c22cecb56eb8ac38b35

Hash scope: SHA-256 of the PDF bytes as downloaded 2026-10-13T12:38:42Z. bioRxiv rewrites the XMP dates and document IDs, the Info ModDate and the trailer /ID on download, so a re-download does not reproduce the hash; the review found a fresh copy differing only in those 43 bytes, with an identical text layer.

Inspected artifact

Hash scope
SHA-256 of the PDF bytes as downloaded 2026-10-13T12:38:42Z. bioRxiv rewrites the XMP dates and document IDs, the Info ModDate and the trailer /ID on download, so a re-download does not reproduce the hash; the review found a fresh copy differing only in those 43 bytes, with an identical text layer.
Source metadata
BioML-bench: Evaluation of AI Agents for End-to-End Biomedical ML

Original source ↗

No field-specific location recorded

Version: bioRxiv 2025.09.01.673319 version 3, posted 2025-09-28 (versions 1 and 2 posted 2025-09-04 and 2025-09-07)
Retrieved: 2026-10-13T12:38:42Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.hash_scope

Source artifact SHA-256: 875cb3519dac9b0ec51c35224e1fc90b107b0676a4cc7c22cecb56eb8ac38b35

Hash scope: SHA-256 of the PDF bytes as downloaded 2026-10-13T12:38:42Z. bioRxiv rewrites the XMP dates and document IDs, the Info ModDate and the trailer /ID on download, so a re-download does not reproduce the hash; the review found a fresh copy differing only in those 43 bytes, with an identical text layer.

Inspected artifact

Licence
CC-BY-4.0
Source metadata
BioML-bench: Evaluation of AI Agents for End-to-End Biomedical ML

Original source ↗

No field-specific location recorded

Version: bioRxiv 2025.09.01.673319 version 3, posted 2025-09-28 (versions 1 and 2 posted 2025-09-04 and 2025-09-07)
Retrieved: 2026-10-13T12:38:42Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.licence

Source artifact SHA-256: 875cb3519dac9b0ec51c35224e1fc90b107b0676a4cc7c22cecb56eb8ac38b35

Hash scope: SHA-256 of the PDF bytes as downloaded 2026-10-13T12:38:42Z. bioRxiv rewrites the XMP dates and document IDs, the Info ModDate and the trailer /ID on download, so a re-download does not reproduce the hash; the review found a fresh copy differing only in those 43 bytes, with an identical text layer.

Inspected artifact

Limitations
10 values
  • Preprint, not peer reviewed. No published version was found (bioRxiv publication API, 2026-10-13).
  • Results are printed only as aggregates: Table 2 over all 24 tasks and Table 4 per domain. Per-task leaderboard percentiles appear only as points in Figures 2 and 4, with no printed values.
  • Table 3 names two protein engineering tasks differently from the repository's task list at commit 673f3d8 (experiments/biomlbench_v0.1a.txt): SPA_STAAU_Tsuboyama_2023 (protein A) versus SBI_STAAM_Tsuboyama_2023_2JVG (immunoglobulin-binding protein Sbi, single substitutions), and PSAE_PICP2_indels versus PSAE_PICP2_Tsuboyama_2023_1PSE (the substitution assay; the repository also holds a separate _indels task). Which of these assays were run is unresolved. The third label difference, CBX4_HUMAN_multi-sub versus CBX4_HUMAN_Tsuboyama_2023_2K28, is the same assay: the repository description of 2K28 says it contains multi-substitution variants of CBX4_HUMAN.
  • Table 4 prints a value with a plus-or-minus spread but its caption does not say what the spread is. Figures 2 and 4 show the same per-domain leaderboard percentiles as mean ± SEM across tasks, and the Table 2 caption refers to the reported SEM.
  • Section 3.4 defines Above Median, Any Medal and Completion Rate over tasks, but the Table 4 values are multiples of 1/(4 x tasks in the domain) (for example 45.8% = 11/24 for 6 protein tasks), which fits counting replicate runs. The denominator is unresolved.
  • Table 4 prints Completion Rate 'NA' for Dummy in the penalized block, while Table 2 prints 100.0 for Dummy overall.
  • All agents were run by the benchmark's authors, who did not build them. B. T. is CTO of ScienceMachine, which provided compute and LLM API resources (Competing Interests; Acknowledgments).
  • Version 3 replaced the STELLA rows for Drug Discovery and Protein Engineering in Table 4 (and STELLA's Table 2 rows) with new values without explaining why in the text; for example STELLA's penalized protein engineering leaderboard percentile is 14.78 in v2 and 34.98 in v3, and its completion rate 87.5 and 100.0. The other agents' rows are unchanged, including their Mean Rank, which leaves the Mean Rank columns of those blocks internally inconsistent (they no longer sum to 15). Those 20 Mean Rank results are marked disputed.
  • Section 4.2 says Biomni leads Protein Engineering with penalties applied; that sentence is unchanged from v2. In v3 Table 4 STELLA has the higher penalized protein engineering leaderboard percentile (34.98 vs 29.93) and Above Median (45.8 vs 25.0); Biomni has the better Mean Rank (2.00 vs 2.33).
  • M. G. is a contract employee of ScienceMachine, as well as B. T. being its CTO (Competing Interests).
Source metadata
BioML-bench: Evaluation of AI Agents for End-to-End Biomedical ML

Original source ↗

No field-specific location recorded

Version: bioRxiv 2025.09.01.673319 version 3, posted 2025-09-28 (versions 1 and 2 posted 2025-09-04 and 2025-09-07)
Retrieved: 2026-10-13T12:38:42Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.limitations

Source artifact SHA-256: 875cb3519dac9b0ec51c35224e1fc90b107b0676a4cc7c22cecb56eb8ac38b35

Hash scope: SHA-256 of the PDF bytes as downloaded 2026-10-13T12:38:42Z. bioRxiv rewrites the XMP dates and document IDs, the Info ModDate and the trailer /ID on download, so a re-download does not reproduce the hash; the review found a fresh copy differing only in those 43 bytes, with an identical text layer.

Inspected artifact

Media type
application/pdf
Source metadata
BioML-bench: Evaluation of AI Agents for End-to-End Biomedical ML

Original source ↗

No field-specific location recorded

Version: bioRxiv 2025.09.01.673319 version 3, posted 2025-09-28 (versions 1 and 2 posted 2025-09-04 and 2025-09-07)
Retrieved: 2026-10-13T12:38:42Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.media_type

Source artifact SHA-256: 875cb3519dac9b0ec51c35224e1fc90b107b0676a4cc7c22cecb56eb8ac38b35

Hash scope: SHA-256 of the PDF bytes as downloaded 2026-10-13T12:38:42Z. bioRxiv rewrites the XMP dates and document IDs, the Info ModDate and the trailer /ID on download, so a re-download does not reproduce the hash; the review found a fresh copy differing only in those 43 bytes, with an identical text layer.

Inspected artifact

How to read the evidence

Sources and history

Release 2026-11-02-a7f03c9e55a5 · Record review: source checked

bioRxiv preprint (version 3) introducing BioML-bench and reporting four agents against human leaderboards.

Release history

No supporting source is linked yet.

Read original source

Download this release (gzip)
Technical metadata and extraction receipts

Stable ID: lit-agents-20261013-biomlbench-source-miller2025-v3

areas
molecular-interactions; protein-function; single-cell
contexts
research
url
https://www.biorxiv.org/content/10.1101/2025.09.01.673319v3
artifact url
https://www.biorxiv.org/content/10.1101/2025.09.01.673319v3.full.pdf
version
bioRxiv 2025.09.01.673319 version 3, posted 2025-09-28 (versions 1 and 2 posted 2025-09-04 and 2025-09-07)
retrieved at
2026-10-13T12:38:42Z
artifact sha256
875cb3519dac9b0ec51c35224e1fc90b107b0676a4cc7c22cecb56eb8ac38b35
doi
10.1101/2025.09.01.673319
publication status
preprint
licence
CC-BY-4.0
media type
application/pdf
source locator
Full artifact bytes; per-record locators on each record
access and reuse
CC-BY-4.0 permits redistribution of the article bytes.
archive note
Not archived in the batch: the PDF is 2,282,513 bytes and the repository keeps releases small. The artifact_sha256 pins the bytes that were read.
extraction method
pdftotext -layout text layer, parsed by extract/extract_biomlbench.py
limitations
Preprint, not peer reviewed. No published version was found (bioRxiv publication API, 2026-10-13).; Results are printed only as aggregates: Table 2 over all 24 tasks and Table 4 per domain. Per-task leaderboard percentiles appear only as points in Figures 2 and 4, with no printed values.; Table 3 names two protein engineering tasks differently from the repository's task list at commit 673f3d8 (experiments/biomlbench_v0.1a.txt): SPA_STAAU_Tsuboyama_2023 (protein A) versus SBI_STAAM_Tsuboyama_2023_2JVG (immunoglobulin-binding protein Sbi, single substitutions), and PSAE_PICP2_indels versus PSAE_PICP2_Tsuboyama_2023_1PSE (the substitution assay; the repository also holds a separate _indels task). Which of these assays were run is unresolved. The third label difference, CBX4_HUMAN_multi-sub versus CBX4_HUMAN_Tsuboyama_2023_2K28, is the same assay: the repository description of 2K28 says it contains multi-substitution variants of CBX4_HUMAN.; Table 4 prints a value with a plus-or-minus spread but its caption does not say what the spread is. Figures 2 and 4 show the same per-domain leaderboard percentiles as mean ± SEM across tasks, and the Table 2 caption refers to the reported SEM.; Section 3.4 defines Above Median, Any Medal and Completion Rate over tasks, but the Table 4 values are multiples of 1/(4 x tasks in the domain) (for example 45.8% = 11/24 for 6 protein tasks), which fits counting replicate runs. The denominator is unresolved.; Table 4 prints Completion Rate 'NA' for Dummy in the penalized block, while Table 2 prints 100.0 for Dummy overall.; All agents were run by the benchmark's authors, who did not build them. B. T. is CTO of ScienceMachine, which provided compute and LLM API resources (Competing Interests; Acknowledgments).; Version 3 replaced the STELLA rows for Drug Discovery and Protein Engineering in Table 4 (and STELLA's Table 2 rows) with new values without explaining why in the text; for example STELLA's penalized protein engineering leaderboard percentile is 14.78 in v2 and 34.98 in v3, and its completion rate 87.5 and 100.0. The other agents' rows are unchanged, including their Mean Rank, which leaves the Mean Rank columns of those blocks internally inconsistent (they no longer sum to 15). Those 20 Mean Rank results are marked disputed.; Section 4.2 says Biomni leads Protein Engineering with penalties applied; that sentence is unchanged from v2. In v3 Table 4 STELLA has the higher penalized protein engineering leaderboard percentile (34.98 vs 29.93) and Above Median (45.8 vs 25.0); Biomni has the better Mean Rank (2.00 vs 2.33).; M. G. is a contract employee of ScienceMachine, as well as B. T. being its CTO (Competing Interests).
hash scope
SHA-256 of the PDF bytes as downloaded 2026-10-13T12:38:42Z. bioRxiv rewrites the XMP dates and document IDs, the Info ModDate and the trailer /ID on download, so a re-download does not reproduce the hash; the review found a fresh copy differing only in those 43 bytes, with an identical text layer.
Related records

Suggest a correction